Sight Sciences publishes results of SAHARA clinical trial for the treatment of dry eye disease
December 21st 2023Interventional eyelid procedures enabled by TearCare technology delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through 6 months.
Read More
Azura CEO gives details on phase 2 study of AZR-MD-001
December 18th 2023Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort.
Read More
Nicox screens first patient in Whistler Phase 3b trial of NCX 470 in glaucoma
December 18th 2023NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is the company’s lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Read More
Machine learning sees into the future to prevent sight loss in humans
December 17th 2023A team of researchers from Tokyo Medical and Dental University have developed models based on machine learning that predict long-term visual acuity in patients with high myopia, one of the top three causes of irreversible blindness in many regions of the world.
Read More
Study: Fish-like genetic program used to turn human Müller glia cells into neurons
December 6th 2023Fish have the built-in ability to regenerate retinal neurons by turning another retinal cell type called Müller glia into neurons. Researchers have been able to coax the human Müller glia into changing identity in the laboratory, which could serve as a potential source of new neurons to treat vision loss.
Read More